Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetesMohammad Alhadj Ali, Colin Dayan, Susanne Heck et al.|Science Translational Medicine|2017Cited by 215
Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trialDanijela Tatović, Laura Cook, Ashish Marwaha et al.|Nature Medicine|2024Cited by 40
Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humansStephanie Hanna, Danijela Tatović|Frontiers in Immunology|2023Cited by 14
The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCTKymberley Carter, Colin Dayan, WY Cheung et al.|Efficacy and Mechanism Evaluation|2025Cited by 2
Relationship between participant-reported outcomes, residual beta cell function and metabolic parameters in youth with newly diagnosed type 1 diabetesPeter Taylor, Colin M. Dayan, Wai-Yee Cheung et al.|Diabetologia|2026Cited by 0